Clinical Trials Directory

Trials / Completed

CompletedNCT02772458

Reduced Appetite in Crohn's Disease: The Role of the Brain in the Control of Food Intake

Reduced Appetite in Crohn's Disease: Investigating the Role of the Gut Brain Pathways

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
80 (actual)
Sponsor
University of Nottingham · Academic / Other
Sex
All
Age
16 Years – 75 Years
Healthy volunteers
Accepted

Summary

Crohn's disease (CD) is becoming more common, specifically in the western world. One of the main features of this disease is weight loss and malnutrition. Although clinically common, these problems are not well understood. Loss of appetite and symptoms such as tummy aches and bloating are common causes for weight loss in this group of patients. This problem has a strong negative effect on the patients' quality of life and significantly increases the cost of treating CD. Enteroendocrine cells are nutrient sensors in the bowel that relay to the brain to control food intake. Recent evidence has showed that these cells increase in number in active CD and secrete more hormones that negatively affect appetite. The increased levels of these hormones should have an overall negative effect on the brain and thus decrease food intake, bloating, symptoms of sickness. All these symptoms lead to malnutrition. These are hypotheses that require further proof. Current technological advances in magnetic resonance imaging (MRI) has enabled the mapping of changes in activity in important areas in the brain that control food intake. The involvement of the brain in control of food intake is still not fully understood. This work will be the first step in the right direction to start targeting the problems of appetite, weight loss and a poor quality of life.

Conditions

Interventions

TypeNameDescription
OTHERDodecanoate acid and salineTest drink

Timeline

Start date
2015-06-01
Primary completion
2018-09-01
Completion
2018-09-01
First posted
2016-05-13
Last updated
2019-04-17

Locations

2 sites across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT02772458. Inclusion in this directory is not an endorsement.